$8.13▴ 1.50%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$82.86MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-10.8%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 25% below our fair-value range
Balance-sheet caution
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Certara, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is contracting year over year. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$-0.45
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-16.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$408.45M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.